Skip to main content
    S

    Strata Critical Medical, Inc. (SRTA)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $5.24
    -0.18 (-3.32%)

    Market Cap: $484.11M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Strata Critical Medical, Inc. (SRTA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Strata Critical Medical (SRTA) has a market cap of $484.11M. Its share count is up 7.06% from a year earlier. Revenue grew 22.73% over the last 12 months from the 12 months before.

    Total Valuation

    Market Cap$484.11M
    Latest price (Nov 17, 2026)$5.24

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.39% in the quarter ended Sep 30, 2026 and grew 6.35% a year over 2 years.

    Shares Outstanding88.27M
    Shares Change (YoY)+7.06%
    Shares Change (QoQ)+2.39%
    Share Count Growth (2Y CAGR)+6.35%

    Valuation Ratios

    Sales and book value multiples are 1.6x and 1.7x.

    P/S Ratio1.6x
    Forward P/S1.7x
    P/B Ratio1.7x
    P/TBV Ratio4.0x
    P/OCF Ratio46.6x

    Price Statistics

    The stock is up 9.39% over 52 weeks and trades 4.38% above its 50-day average.

    Beta (1Y)1.88
    52-Week Change+9.39%
    1-Month Change+15.42%
    3-Month Change-11.04%
    6-Month Change+0.38%
    Total Return (1Y)+9.39%
    Return vs SPY (1Y)+7.26%
    Max Drawdown (1Y)-33.85%
    Sharpe Ratio (1Y)0.31
    Correlation with SPY (1Y)0.47
    50-Day Average$5.02
    200-Day Average$5.10
    52-Week Range$3.95 to $6.50
    RSI (14 Days)51.4
    Average Volume (20 Days)1.24M

    Financial Position

    Current assets cover 2.77x current liabilities.

    Current Ratio2.77x
    Quick Ratio2.77x

    Returns and Efficiency

    Return on equity is -8.98% over the last 12 months, against a 5-year average of -9.02%.

    Return on Equity (ROE)-8.98%
    Return on Assets (ROA)-7.54%
    Return on Capital Employed (ROCE)-6.98%
    ROE (5Y Average)-9.02%
    ROA (5Y Average)-7.45%
    ROIC (5Y Average)-12.41%
    Asset Turnover0.85x
    Inventory Turnover2718.73x
    Receivables Turnover6.52x
    Cash Conversion Cycle29 days

    Scores

    SRTA has an Altman Z-Score of 5.54, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score5.54
    Altman Z ZoneSafe
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $280.76M over the last 12 months.

    Revenue$280.76M
    Revenue Growth (YoY)+22.73%
    Gross Profit$57.82M
    Operating Income-$18.62M
    Pretax Income-$21.12M
    Net Income-$24.81M
    EBITDA-$9.02M
    EBIT-$19.82M
    Reported EPS (TTM)-$0.14

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 84.04% of the $328.88M in total assets.

    Cash and Equivalents$35.14M
    Working Capital$80.02M
    Shareholder Equity$276.38M
    Book Value Per Share$3.13
    Tangible Book Value$115.63M
    Tangible Book Per Share$1.31
    Total Assets$328.88M
    Total Liabilities$52.51M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $10.07M of capital spending, operating cash flow left $320.00K of free cash flow.

    Operating Cash Flow$10.39M
    Capital Expenditures$10.07M
    Free Cash Flow$320.00K
    FCF Per Share$0.00
    Depreciation and Amortization$21.89M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -6.63%, against a 5-year average of -27.91%.

    Gross Margin20.59%
    Operating Margin-6.63%
    Pretax Margin-7.52%
    Net Margin-8.84%
    EBITDA Margin-3.21%
    EBIT Margin-7.06%
    FCF Margin0.11%
    Gross Margin (5Y Average)19.86%
    Operating Margin (5Y Average)-27.91%
    Net Margin (5Y Average)-22.57%

    Growth

    Revenue grew 10.50% a year over 3 years.

    Revenue Growth (3Y CAGR)+10.50%
    Revenue Growth (5Y CAGR)+53.10%
    Book Value Per Share Growth (2Y CAGR)+3.85%
    Tangible Book Per Share Growth (2Y CAGR)-13.48%

    Revenue and profit by year

    Dividends and Yields

    SRTA does not pay a dividend. Its free cash flow yield is 0.07%.

    FCF Yield0.07%
    Shareholder Yield0.00%

    Peer Position

    Against 8 similar companies, SRTA has the 4th highest P/S.

    P/S Ratio1.6x vs 1.3x median
    Revenue Growth (Trailing 4 Quarters, YoY)+22.73% vs +4.85% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 28.41% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+28.41%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SRTA

    What is SRTA's market cap?

    Strata Critical Medical has a market cap of $484.11M.

    How many shares of SRTA are outstanding?

    Strata Critical Medical has 88.27M shares outstanding. The count is up 7.06% from a year earlier.

    Does SRTA pay a dividend?

    No. Strata Critical Medical does not pay a dividend.